• Home
  • Research papers
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market Research Report 2021 – Global Growth, Trends, COVID-19 Impact, and Forecast to 2026 – ResearchAndMarkets.com | Company

Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market Research Report 2021 – Global Growth, Trends, COVID-19 Impact, and Forecast to 2026 – ResearchAndMarkets.com | Company

By on August 5, 2021 0


DUBLIN – (BUSINESS WIRE) – August 5, 2021–

The report “Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Market – Growth, Trends, Impact of COVID-19 and Forecast (2021 – 2026)” has been added to the offering of ResearchAndMarkets.com.

The studied nonsteroidal anti-inflammatory drugs (NSAIDs) market is expected to grow at an estimated CAGR of 5.2%, during the forecast period.

The global NSAID market will have a significant impact of Covid-19 on the use and prescribing of NSAID drugs and the future depends on the results of various ongoing trials to understand the effect of NSAIDs on Covid patients.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs. These are widely used in the treatment of pain and inflammation. The growing burden of chronic pain and inflammation is boosting demand for NSAIDs. NSAIDs are also widely used for the treatment of chronic inflammatory disorders such as rheumatoid arthritis and spondylitis.

They are preferred over other medications because they are inexpensive and help manage the chronic pain, inflammation, and swelling that are characteristic of rheumatoid arthritis. Globally, there is an increase in the prevalence and incidence rates of rheumatoid arthritis (RA).

According to an article by Khalid Almutairi (2021) titled “The Global Prevalence of Rheumatoid Arthritis: A Meta-Analysis Based on a Systematic Review”, the global prevalence of RA in 2019 was 460 per 100,000 population, with variations due to the geographical location. According to the Centers for Disease Control and Prevention, by 2040, an estimated 78 million (26%) American adults aged 18 or older will be diagnosed with arthritis. Considering all the facts mentioned, the NSAID market is expected to witness significant growth during the forecast period.

However, the side effects caused by the use of NSAIDs are a major obstacle to the growth of the market. The main therapeutic actions of NSAIDs are produced by their ability to inhibit cyclooxygenase enzymes (COX-1 and COX-2). The desired effect of the anti-inflammatory, antipyretic and analgesic response of NSAIDs is due to its inhibition of COX-2; while inhibition of COX-1 plays a major role in unwanted side effects such as gastrointestinal and renal toxicities. This is expected to negatively impact the growth of the nonsteroidal anti-inflammatory drugs market.

Competitive landscape

The NSAID market is very competitive with several players around the world. In terms of market share, few of the major players currently dominate the market. With increasing research and development activities, many regional players are expected to contribute to the NSAID market during the forecast period.

Some of the major market players are Pfizer Inc., GlaxoSmithKline Plc, Johnson & Johnson, Bayer AG, Sanofi SA, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd, Iroko Pharmaceuticals Inc., Reckitt Benckiser Group PLC, Assertio Therapeutics, Inc. and d ‘others.

Main topics covered:





4.1 Market overview

4.2 Market drivers

4.2.1 Growing Burden of Chronic Pain and Inflammation

4.2.2 Preference of NSAIDs over other classes of analgesics

4.3 Market restrictions

4.3.1 High cost of drug development and launches

4.3.2 Side effects of NSAIDs

4.4 Porter’s five forces analysis


5.1 By route of administration

5.1.1 Oral

5.1.2 Parenteral

5.2 By application

5.2.1 Arthritis

5.2.2 Migraine

5.2.3 Ophthalmic diseases

5.2.4 Other applications

5.3 By distribution channel

5.3.1 Hospital pharmacies

5.3.2 Retail pharmacies

5.3.3 Other distribution channels

5.4 Geography


6.1 Company profiles

6.1.1 Pfizer Inc.

6.1.2 GlaxoSmithKline Plc

6.1.3 Johnson & Johnson

6.1.4 Bayer SA

6.1.5 Sanofi SA

6.1.6 Horizon Therapeutics plc

6.1.7 Sun Pharmaceutical Industries Ltd

6.1.8 Iroko Pharma inc.

6.1.9 Reckitt Benckiser Group PLC

6.1.10 Assertio Therapeutics, Inc.


For more information on this report, visit https://www.researchandmarkets.com/r/albjv1

See the source version on businesswire.com: https://www.businesswire.com/news/home/20210805005596/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Director

[email protected]

For EST office hours, call 1-917-300-0470

For USA / CAN call toll free 1-800-526-8630

For GMT office hours, call + 353-1-416-8900



SOURCE: Research and markets

Copyright Business Wire 2021.

PUB: 08/05/2021 07:25 / DISC: 08/05/2021 07:26 AM


Recent stories you may have missed

Copyright Business Wire 2021.


Leave a comment

Your email address will not be published.